Figure 5.
Efficacy evaluation of OralGem’s daily low dose administration in a syngeneic lung tumor model. (A) IC50 values of gemcitabine and OralGem on the Lewis lung carcinoma (LLC-OVA) cell line. Experiments were performed in triplicates, and statistical analysis was performed via t-test (n = 3). (B,C) Lungs bearing LLC-OVA tumors were resected from control, MTD, MTR-treated mice, in which LLC-OVA cells (5 × 105 cells) were injected via the tail vein. Seven days after cell inoculation, mice were divided randomly into 3 groups. Lungs were evaluated macroscopically (A), whereas the big lung lobe was studied stereoscopically (B) (1x magnification) in H&E stained sections; control group (n = 6–8) that received no treatment, MTD group (n = 6–8) treated with gemcitabine 120 mg/kg for 4 times in 12 days, MTR group (n = 6–8) treated with OralGem 6 mg/kg for 11 days daily, are shown. The yellow arrows show the formed tumors, and the yellow circle the thymuses. Macroscopic evaluation of thymus toxicity was also performed. (D) Whole blood was collected for analysis of WBCs and (E) RBCs numbers. Data are mean ± SD. Statistical analysis was performed by Student’s t-test; ** p < 0.01 and *** p < 0.001. (F) Representative H&E staining of the thymuses, as indicated (1x magnification in the stereoscope). Data obtained by five [5] experiments.